Skip to main content
    C

    Charles River Laboratories (CRL)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $335.46
    -2.51 (-0.74%)

    Market Cap: $16.19B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Charles River Laboratories (CRL) Earnings: Report Dates and Results

    Updated Nov 4, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Charles River Laboratories (CRL) is expected to report earnings on Feb 16, 2027. In the quarter ended Sep 30, 2026, Charles River Laboratories reported EPS of $3.09, above the $2.98 estimate. It beat the EPS estimate in each of the last 40 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    100%(40/40)
    Avg Surprise
    +9.31%
    Streak
    45 Q

    Upcoming Estimates

    Reports Feb 16, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$3.35
    Range$3.16 - $3.56
    15 analysts
    Revenue Consensus
    $979.02M
    Range$923.26M - $1.06B
    15 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$2.87
    Range$2.48 - $3.13
    7 analysts
    EPS Estimate DriftChange to current
    90d ago$2.79+2.7%
    60d ago$2.79+2.7%
    30d ago$2.84+1.1%
    7d ago$2.86+0.1%
    Current$2.87
    Revenue Consensus
    $991.30M
    Range$969.20M - $1.02B
    6 analysts

    Next Report

    CRL has an expected report date of Feb 16, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 40.2% above the $2.39 reported for the quarter ended Dec 31, 2025.

    CRL Earnings Call

    The latest CRL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Revenue for the quarter ended Sep 30, 2026 was $982.73M, down 1.7% from $1.00B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$3.09$2.98$2.93 - $3.09+3.69%Beat+27.2%136 up, 1 downNov 4, 2026$982.73M
    Jun 30, 2026$3.02$2.72$2.58 - $2.91+11.03%Beat-3.2%12N/AAug 5, 2026$1.00B
    Mar 31, 2026$2.06$1.95$1.91 - $2.11+5.64%Beat-12.0%132 up, 4 downMay 7, 2026$995.83M
    Dec 31, 2025$2.39$2.33$2.25 - $2.44+2.58%Beat-10.2%142 up, 1 downFeb 18, 2026$994.23M
    Sep 30, 2025$2.43$2.32$2.30 - $2.48+4.74%Beat-6.2%141 up, 1 downNov 5, 2025$1.00B
    Jun 30, 2025$3.12$2.55$2.46 - $2.57+22.35%Beat+11.4%143 up, 0 downAug 6, 2025$1.03B
    Mar 31, 2025$2.34$2.07$2.00 - $2.27+13.04%Beat+3.1%153 up, 6 downMay 7, 2025$984.17M
    Dec 31, 2024$2.66$2.53$2.45 - $2.64+5.14%Beat+8.1%160 up, 5 downFeb 19, 2025$1.00B
    Sep 30, 2024$2.59$2.42$2.36 - $2.49+7.02%Beat-4.8%153 up, 0 downNov 6, 2024$1.01B
    Jun 30, 2024$2.80$2.39$2.36 - $2.43+17.15%Beat+4.1%161 up, 0 downAug 7, 2024$1.03B
    Mar 31, 2024$2.27$2.06$2.00 - $2.11+10.19%Beat-18.3%130 up, 0 downMay 9, 2024$1.01B
    Dec 31, 2023$2.46$2.40$2.25 - $2.48+2.50%Beat-17.4%130 up, 0 downFeb 14, 2024$1.01B
    Sep 30, 2023$2.72$2.37$2.33 - $2.51+14.77%Beat+3.4%142 up, 0 downNov 8, 2023$1.03B
    Jun 30, 2023$2.69$2.64$2.61 - $2.66+1.89%Beat-2.9%131 up, 0 downAug 9, 2023$1.06B
    Mar 31, 2023$2.78$2.59$2.53 - $2.62+7.34%Beat+1.1%140 up, 0 downMay 11, 2023$1.03B
    Dec 31, 2022$2.98$2.75$2.68 - $2.79+8.36%Beat+19.7%140 up, 0 downFeb 22, 2023$1.10B
    Sep 30, 2022$2.63$2.50$2.39 - $2.64+5.20%Beat-2.6%134 up, 0 downNov 2, 2022$989.16M
    Jun 30, 2022$2.77$2.74$2.68 - $2.81+1.09%Beat+6.1%132 up, 1 downAug 3, 2022$973.13M
    Mar 31, 2022$2.75$2.72$2.68 - $2.76+1.10%Beat+8.7%122 up, 1 downMay 4, 2022$913.93M
    Dec 31, 2021$2.49$2.43$2.39 - $2.47+2.47%Beat+4.2%12N/AFeb 16, 2022$905.05M
    Sep 30, 2021$2.70$2.58$2.46 - $2.65+4.65%Beat+15.9%11N/ANov 3, 2021$895.94M
    Jun 30, 2021$2.61$2.38$2.03 - $2.49+9.66%Beat+65.2%13N/AAug 4, 2021$914.61M
    Mar 31, 2021$2.53$2.19$2.06 - $2.33+15.53%Beat+37.5%14N/AMay 4, 2021$824.57M
    Dec 31, 2020$2.39$2.11$2.04 - $2.30+13.27%Beat+18.9%16N/AFeb 17, 2021$790.99M
    Sep 30, 2020$2.33$1.80$1.66 - $1.86+29.44%Beat+37.9%15N/AOct 29, 2020$743.30M
    Jun 30, 2020$1.58$1.28$1.21 - $1.40+23.44%Beat-3.1%16N/AAug 5, 2020$682.58M
    Mar 31, 2020$1.84$1.46$1.39 - $1.57+26.03%Beat+31.4%12N/AMay 7, 2020$707.06M
    Dec 31, 2019$2.01$1.83$1.82 - $1.87+9.84%Beat+34.9%15N/AFeb 11, 2020$691.14M
    Sep 30, 2019$1.69$1.64$1.59 - $1.71+3.05%Beat+10.5%12N/ANov 6, 2019$667.95M
    Jun 30, 2019$1.63$1.55$1.52 - $1.60+5.16%Beat+0.6%13N/AJul 31, 2019$657.57M
    Mar 31, 2019$1.40$1.39$1.32 - $1.44+0.72%Beat+1.4%13N/AMay 7, 2019$604.57M
    Dec 31, 2018$1.49$1.40$1.37 - $1.45+6.43%Beat+6.4%16N/AFeb 13, 2019$601.53M
    Sep 30, 2018$1.53$1.38$1.36 - $1.40+10.87%Beat+17.7%16N/ANov 7, 2018$585.29M
    Jun 30, 2018$1.62$1.46$1.44 - $1.51+10.96%Beat+25.6%15N/AAug 8, 2018$585.30M
    Mar 31, 2018$1.38$1.26$1.23 - $1.34+9.52%Beat+7.0%14N/AMay 10, 2018$493.97M
    Dec 31, 2017$1.40$1.25$1.20 - $1.28+12.00%Beat+15.7%15N/AFeb 13, 2018$478.48M
    Sep 30, 2017$1.30$1.22$1.21 - $1.24+6.56%Beat+10.2%15N/ANov 9, 2017$464.23M
    Jun 30, 2017$1.29$1.22$1.20 - $1.25+5.74%Beat+7.5%16N/AAug 9, 2017$469.13M
    Mar 31, 2017$1.29$1.14N/A+13.16%Beat+31.6%N/AN/AMay 10, 2017$445.76M
    Dec 31, 2016$1.21$1.11N/A+9.01%Beat+21.0%N/AN/AFeb 14, 2017$466.79M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $10.28, within 4 cents of the year before. It was $4.57 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$10.28N/A
    Dec 31, 2024$10.32-3.1%
    Dec 31, 2023$10.65-4.3%
    Dec 31, 2022$11.13+7.7%
    Dec 31, 2021$10.33+26.9%
    Dec 31, 2020$8.14+21.0%
    Dec 31, 2019$6.73+11.8%
    Dec 31, 2018$6.02+14.0%
    Dec 31, 2017$5.28+15.5%
    Dec 31, 2016$4.57N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,700 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,70913
    2026Q2Jun 30, 202610,82515
    2026Q1Mar 31, 20268,75317
    2025Q4Dec 31, 202510,02610
    2025Q3Sep 30, 20258,98912
    2025Q2Jun 30, 20258,91512
    2025Q1Mar 31, 20258,80613
    2024Q4Dec 31, 20249,09114

    2026Q3 Earnings Call

    Opening remarks

    Todd Spencer Vice President, Investor Relations Good morning, and welcome to Charles River Laboratories Third Quarter 2026 Earnings Conference Call and Webcast. This morning, I am pleased to be joined by Birgit Girshick, our Chief Executive Officer, and by Glenn Coleman, our Executive Vice President and Chief Financial Officer. They will comment on our results for the third quarter of 2026, as well as our financial guidance. Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks, which will be posted on the Investor Relations section of our website at ir.criver.com. A webcast replay of this call will be available beginning approximately two hours after the call today and can also be accessed on the Investor Relations website. The replay will be available through next quarter's conference call. I'd like to remind you of our safe harbor. All remarks that we make about future expectations, plans, and prospects for the company constitute forward-looking statements under federal securities law, including the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated. During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and the reconciliations on the Investor Relations section of our website. I will now turn the call over to Birgit Girshick.

    Birgit Girshick Chief Executive Officer Thank you, Todd, and good morning. We are pleased today to report another solid quarter with revenue and non-GAAP earnings per share that exceeded our prior outlook, continued momentum in the improving biopharmaceutical demand environment, and additional progress toward the execution of our Pathway to Purpose strategic vision. It was wonderful to see many of you at our Investor Day just over one month ago, and I hope that you found it to be an informative discussion about our strategic initiatives designed to enhance our operational excellence and strengthen our scientific leadership, as well as our future growth drivers and long-term financial targets. As I mentioned, our focus is to simplify the company and move faster, invest where we can win, and continue to lead as the scientific partner of choice for the critical work that our clients do. By executing on these goals, we believe it will translate into higher growth and operating margins and drive long-term shareholder value creation.

    Frequently Asked Questions About CRL

    When is Charles River Laboratories's next earnings date?

    Charles River Laboratories's next earnings report is expected for Feb 16, 2027.

    Did CRL beat earnings estimates last quarter?

    Yes. Charles River Laboratories reported EPS of $3.09 for the quarter ended Sep 30, 2026, above the $2.98 estimate, a 3.69% surprise.

    What EPS do analysts expect from CRL next quarter?

    The consensus EPS estimate for Charles River Laboratories for the quarter ending Dec 31, 2026 is $3.35 from 15 analysts, with estimates from $3.16 to $3.56.

    How often does CRL beat earnings estimates?

    Charles River Laboratories beat the EPS estimate in each of the last 40 quarters, with an average surprise of +9.31%.